Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

NCT06456138 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

KRAS Mutation-Related Tumors
Advanced Lung Cancer
Refractory Tumor

Interventions

DRUG: Trametinib
DRUG: Anlotinib
DRUG: Tislelizumab

Sponsor

Shanghai Chest Hospital

Collaborators

[object Object]
[object Object]
[object Object]